мȸ ǥ ʷ

ǥ : ȣ - 540611   255 
Impact of antihypertensive therapy on dyssynchrony in patients with never-treated and uncomplicated hypertension
가톨릭 의과대학 성바오로 병원
권범준, 최규영, 김동빈, 장성원, 조은주, 윤호중, 이만영, 정욱성, 승기배, 노태호, 김재형
Background: The impact of antihypertensive therapy on dyssynchrony in patients with never-treated and uncomplicated hypertension has not been explored. Methods: Fourty two patients of never-treated and uncomplicated hypertension (47.6% men, mean age 55.6 ± 9.9 years) underwent echocardiographic evaluations of dyssynchrony at baseline and after 6 months of antihypertensive therapy. Measured parameters were as follows: i) standard deviation of time from ECG Q to systolic peak velocity of 12 Left ventricular (LV) segments (ms, Ts-SD12) and maximum difference of time to systolic peak velocity among 12 LV segments (ms, Ts-Max) (systolic dyssynchrony); (ii) sum of time exceeding aortic closure in strain curves of 12 LV segments (ms, oExcT) (contractile diastolic dyssynchrony); (iii) SD of time from ECG Q to early diastolic peak velocity of 12 LV segments (ms, Te-SD12) and maximum difference of time to early diastolic velocity among 12 LV segments (ms, Te-Max) (diastolic dyssynchrony). Ts-SD12 ≥33ms or Ts-Max ≥100ms was regarded as systolic dyssynchrony. Patients with systolic dyssynchrony (group 1, N=18) and without systolic dyssynchrony (group 2, N=24) at baseline were compared. Results: The echocardiographic parameters were summarized in the table. In group 1 patients, systolic (Ts-SD12, Ts-Max) and diastolic (Te-Max) dyssynchrony, and LV mass index (LVMI) significantly improved after antihypertensive therapy. However, there were no significant differences except oExcT in group 2 patients. Conclusions: Antihypertensive therapy could reverse the echocardiographic parameters of dyssynchrony in patients with hypertension and systolic dyssynchrony.

 

 

Dyssynchrony

at baseline (N=18)

No Dyssynchrony

at baseline (N=24)

Total population

(N=42)

baseline

Follow-UP

P value

baseline

Follow-UP

P value

baseline

Follow-Up

P value

Ts-SD12 (ms)

44.4±8.7

33.4±11.1*

0.008

23.3±7.8

26.2±15.3

0.596

32.3± 13.3

29.3± 14.0

0.225

Ts-Max (ms)

120.7±30.0

97.1±38.2*

0.011

68.3±26.2

77.1±46.0

0.454

90.8± 85.6

85.6± 43.5

0.132

oExcT (ms)

525.4±309.9

416.9±215.4

0.270

576.7±313.6

412.5±160.8*

0.017

554.7± 309.1

414.4± 183.7*

0.013

Te-SD12 (ms)

23.9±13.1

18.4±5.1

0.087

23.3± 13.6

24.5± 12.3

0.605

23.6± 13.2

21.9± 10.2

0.380

Te-Max (ms)

80.8±57.2

57.2±14.1*

0.031

72.7±39.3

76.8±39.0

0.559

76.1± 41.1

68.4± 32.1

0.220

LVMI

(g/m2)

102.3±32.4

91.6±25.3*

0.037

103.6±26.5

97.3±27.3

0.237

103.1±94.8

94.8± 26.3*

0.025

ESV (ml)

22.5±7.8

21.9±7.5

0.782

21.4±9.7

22.2±8.0

0.663

21.9±8.9

22.0±7.7

0.911

EF (%)

65.8±5.4

65.4±6.0

0.797

66.1±6.7

63.1±8.3

0.095

65.9±6.1

64.1±7.4

0.115

HR (BPM)

69±8

68±12

0.721

70±10

71± 10

0.538

69±9

69±4

0.927

  *P<0.05 compared with baseline



[ư]


logo 학술대회일정 사전등록안내 초록등록안내 초록등록/관리 숙박 및 교통 안내 전시 및 광고